Automated manufacturing
Automated manufacturing of ATMPs
The overall goal is to explore and develop automated manufacturing in closed systems for ATMP production.
Time period: 05/2021 – 12/2023
Lead: Malin Parmar, Lund University
Partners: Lund University, Skåne University Hospital (SUS), Miltenyi Biotec’
Automated manufacturing of ATMPS in closed systems facilitates clinical translation of novel cell therapies by reducing cleanroom requirements and standardising cell manufacturing. The project explores automated manufacturing procedures using two ongoing translational cell therapy projects with different requirements for manufacturing;
- Dopamine neuron cell replacement for Parkinson’s Disease, produced from pluripotent stem cells, small scale per patient
- Mesenchymal stem cells/mesenchymal stromal cells (MSCs) expansion at relatively large scale per patient for lung repair
Work Plan:
Dopamine neurons
- ongoing translational effort (STEM-PD program), use of CliniMACS Prodigy® Adherent Cell Culture (ACC) System and the PSC-mDA Neuron Phenotyping Kit, production, testing and optimization of DA batches
MSCs
- Production of BM-derived MSCs, CliniMACS Prodigy® Adherent Cell Culture (ACC) System and MSC Phenotyping Kit, pig lung injury xenotransplantation model, human lung model